Yahoo Finance

Beacon Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for laru-zova (AGTC-501)

LONDON and CAMBRIDGE, Mass., Jan. 28, 2025 /PRNewswire/ -- Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading ophthalmic gene therapy company with a mission to ...
Yahoo Finance

Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP

LONDON and CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited ("Beacon Therapeutics" or "the Company"), a leading clinical-stage biotechnology company with a ...
Hosted on MSN

Enrolment concludes in Beacon Therapeutics’ trial of laru-zova for XLRP

Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova (laruparetigene zovaparvovec) as a potential treatment for X-linked retinitis ...
Nasdaq

Beacon Therapeutics Announces Positive Interim Data from Phase 2 DAWN Trial of Laru-zova in Patients with X-Linked Retinitis Pigmentosa

Beacon Therapeutics reports promising 6-month data on laru-zova, showing visual function improvements in XLRP patients from the DAWN trial. Beacon Therapeutics announced promising interim results from ...
Healio

Laru-zova shows safety, low luminance visual acuity gains in X-linked retinitis pigmentosa

Please provide your email address to receive an email when new articles are posted on . Laru-zova demonstrated a positive safety profile and early efficacy in improving low luminance visual acuity in ...